Patient P-02682
Synthetic patientMETA-24 · Day 147 · 55–64 · F · baseline S13Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
12%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S13
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Inflammatory activity-6
- Nutritional resilience-2
- Treatment adherence+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable88 min
stable · -0.1 vs previous 14 d
Sleep duration
Wearable5.7 h
stable · +0.0 vs previous 14 d
Energy level
Daily log6.5/10
worsening · -0.5 vs previous 14 d
Steps
Wearable9,579
stable · -83 vs previous 14 d
GI burden
Companion17.4/100
worsening · +5.1 vs previous 14 d
Adherence
Companion94.8 %
stable · +3.6 vs previous 14 d
Sleep quality
Wearable34.9/100
improving · +2.0 vs previous 14 d
Glucose, CGM daily mean
CGM138 mg/dL
stable · +1.9 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 95 from the failing basin, 10 from restoration.
Good elements to keep
- Protein (supports)perturbation · steering +10.4
- Butyrate producers intacthidden · steering +7.5
- Proteinsupporter · GI -5 next day
Main detractors to watch
- Rapid metabolizerhidden · steering -8
- Poor-sleep weekperturbation · steering -3
- Dietary driftperturbation · steering -2.6
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-5supporter · 95%
- Dietary fat load+1.5no signal · 30%
- Ultra-processed food+1.4no signal · 32%
- Histamine load-0.6no signal · 15%
- Simple carbohydrates-0.6no signal · 15%
- Alcohol+0.6no signal · 15%
- Caffeine-0.4no signal · 15%
- Insoluble fibre-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓40
- MicrobiomeAkkermansia low → thinner mucus layer
- WearableSleep 5.7 h, below personal baseline
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↑20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 4 · butyrate capacity 78/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 39 ms
- Sleep
- 6.1 h
- Steps
- 9,448
- Resting HR
- 63 bpm
Daily log: GI score 17, nutritional resilience 68, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02337 | 35% | S18 | DT-01 | no change | 100 |
| P-02249 | 41% | S09 | DT-01 | improved | 100 |
| P-02189 | 35% | S17 | — | — | 96 |
| P-02640 | 37% | S03 | — | — | 96 |
| P-02242 | 37% | S20 | — | — | 95 |
| P-02013 | 39% | S14 | BR-03 | no change | 94 |
| P-02104 | 41% | S15 | — | — | 94 |
| P-02450 | 44% | S12 | NP-02 | improved | 92 |
| P-02277 | 45% | S05 | AD-05 | improved | 92 |
| P-02304 | 42% | S15 | — | — | 92 |
| P-02653 | 33% | S14 | — | — | 91 |
| P-02689 | 33% | S13 | — | — | 91 |